Merck is bracing for the years of sales growth from oncology superstar Keytruda to take a sharp turn in 2028—and for more ...

Merck's Q4 2024 results surpassed expectations, driven by strong oncology sales and growth in Keytruda. See why I think MRK ...

Keytruda has been approved since 2016 as a second-line option after chemotherapy for patients with more advanced HNSCC that ...

Merck (NYSE:MRK) shares snaps six straight sessions of gains, as the stock closed 2.2% lower at $89.38 on Wednesday.

We recently published a list of 10 Best Retirement Stocks to Buy According to Hedge Funds. In this article, we are going to ...

China’s DeepSeek shocked the world by delivering unexpected innovation at an unbelievable price. But this disruptive trend ...

Ivonescimab, the new drug, was found in a trial conducted in China to have bested Keytruda, the blockbuster medication ...

The funding comes as Eikon, run by former Merck research chief Roger Perlmutter, has started a Phase 3 trial testing one of ...

Chinese biotech company Akeso developed a lung cancer drug Ivonescimab, which outperformed Merck's Keytruda in trials. This ...

GenBioPro, the largest manufacturer of abortion pills in the U.S., is wading into a federal court case over abortion access ...

Receiving Fast Track designation for PYX-201 from the FDA marks a significant milestone for Pyxis Oncology, recognizing our potential to address the significant medical need in R/M HNSCC. This ...